Naviscon

Naviscon is used for the symptomatic relief of gastro-esophageal reflux and associated acid-related digestive symptoms^{[1] [2]} 

• Gastro-oesophageal reflux (GERD/GORD): Relief of acid regurgitation, heartburn and reflux-related indigestion.^{[1] [2]} 
• Reflux-related indigestion: Relief of indigestion associated with reflux, including symptoms occurring after meals.^{[1] [2]} 
• Hyperacidity: Relief of symptoms associated with excess stomach acid.^[1] 
• Pregnancy-related heartburn: Relief of heartburn and reflux symptoms during pregnancy, where included in the product's approved labeling. ^{[1] [5]} 

রেজিস্টার্ড চিকিৎসকের নির্দেশনা অনুযায়ী ঔষধ সেবন করুন।

• Adults and Adolescents (12 years and older):
• Oral suspension: 10–20 mL after meals and at bedtime, up to four times daily. The maximum daily dose for Oral Suspension is 80 mL.^{[1] [2]} 
• Tablets: The dose depends on the specific formulation. Do not assume that a tablet is equivalent to 10–20 mL of suspension.^[1] 
• Children under 12 years:
• Administration should follow the specific product's approved labeling and medical advice. The reviewed Gaviscon Double Action label recommends use only on medical advice in children under 12 years. Acidex provides a specific dose for children aged 6–12 years; it is not recommended under 6 years.^{[1] [2]} 
• Elderly:
• No routine dosage adjustment is required according to the reviewed product information.^{[1] [2]} 
• Renal or Hepatic Impairment:
• Use with caution, particularly in patients requiring a severely restricted sodium diet. Consider the product's sodium and calcium content and the patient's clinical condition.^{[1] [2]} 
• Administration:
• Shake suspension well before use.
• Administer orally after meals and at bedtime for optimal symptom control.
• If symptoms persist or treatment is needed continuously for more than 7 days, seek medical advice. ^{[1] [2]} 

রেজিস্টার্ড চিকিৎসকের নির্দেশনা অনুযায়ী ঔষধ সেবন করুন।

Naviscon provides symptomatic relief of gastro-oesophageal reflux through a combination of physical barrier formation and gastric acid neutralization.^{[1] [2]} 

• Sodium Alginate: In the acidic environment of the stomach, alginate forms a viscous gel. In the presence of bicarbonate-generated carbon dioxide, the gel forms a floating “raft” over the stomach contents, helping reduce reflux of acidic gastric contents into the oesophagus.^{[1] [1]} 
• Sodium Bicarbonate: Reacts with gastric hydrochloric acid to neutralize acidity and release carbon dioxide. The gas becomes trapped within the alginate gel, helping the raft float on the stomach contents.^{[1] [2]} 
• Calcium Carbonate: Neutralizes gastric hydrochloric acid, reducing stomach acidity. It also contributes carbon dioxide during the neutralization reaction, supporting raft formation. Calcium ions help strengthen the alginate gel structure.^{[1] [2]} 

Overall action: The combination creates a physical barrier that helps limit acid reflux while the antacid ingredients neutralize gastric acid. These complementary actions help relieve heartburn, acid regurgitation and other reflux-related symptoms.^{[1] [2]} 

• Absorption: The combination acts primarily within the gastrointestinal tract, and its therapeutic action does not depend on systemic absorption. Sodium bicarbonate can be absorbed from the intestine, while calcium absorption from calcium carbonate is limited and variable.^[2] 
• Distribution: The alginate-based reflux barrier acts locally in the stomach. The selected product information does not provide detailed distribution data for the combination or quantify the systemic distribution of absorbed ingredients.^[1] 
• Metabolism: The selected product information does not provide detailed ingredient-specific metabolism data for the combination. Sodium alginate primarily acts by forming a physical gel barrier, while sodium bicarbonate and calcium carbonate neutralize gastric acid.^{[1] [2]} 
• Excretion: The reviewed product information does not establish ingredient-specific excretion rates for this combination. Therefore, claims that sodium alginate is always eliminated unchanged in faeces or that excess sodium and calcium are exclusively excreted by the kidneys cannot be confirmed from these sources.^[2] 
• Onset of Action: The product reacts rapidly with gastric acid to form a protective alginate raft. One product-specific patient leaflet reports onset within 3–4 minutes; this timing should not be generalized to every formulation.^{[1] [6]} 
• Half-life: A defined plasma elimination half-life for this combination is not provided in the reviewed product information. A single half-life value should not be assigned to the combination.^{[1] [2]} 

• Pregnancy: May be used during pregnancy when needed, according to product-specific instructions. Available data are reassuring, but fetal risk cannot be ruled out completely.^{[1] [2]} 
• Lactation: Generally considered compatible with breastfeeding when used at recommended doses.^{[4] [5]} 
• Pregnancy Category: No formal FDA pregnancy category assigned.^{[1] [5]} 

• Primary Therapeutic Class: Antacid and reflux suppressant.
• Subclass: Alginate-based antacid combination.^[1] 

• Hypersensitivity: Allergy to any active ingredient or excipient.^[2] 
• Hypercalcaemia or metabolic alkalosis: Use is not recommended without product-specific guidance.^[1] 
• Severe renal impairment or sodium overload risk: Use cautiously; these are not universal contraindications.^{[1] [2]} 

• Renal Impairment: Use cautiously, especially in patients requiring sodium restriction. ^{[1] [2]} 
• Metabolic Alkalosis: Avoid excessive or prolonged use.^[1] 
• Hypercalcaemia: Use cautiously in patients predisposed to elevated calcium levels.^[2] 
• Drug and Mineral Interactions: Separate administration from interacting oral medicines as directed by the product label; seek advice before combining with other sodium- or calcium-containing products.^{[1] [2]} 

• Common: Mild gastrointestinal disturbances such as nausea, constipation, flatulence, or diarrhea.
• Uncommon: Abdominal discomfort, bloating.
• Rare: Hypercalcemia, metabolic alkalosis, allergic reactions including rash, pruritus, angioedema.
• Side effects are generally mild and dose-dependent.^[1] 

• Reduced Drug Absorption: May reduce absorption of tetracyclines, fluoroquinolones, iron salts, thyroid hormones, digoxin, and bisphosphonates. Separate administration by at least 2 hours or follow the specific medicine’s instructions.^{[1] [2]} 
• Other Interactions: Consult a healthcare professional before combining with other calcium- or sodium-containing products. Specific interactions with lithium, salicylates, CYP450 enzymes, and alcohol are not established by the selected references.^{[1] [2] [5]} 

• Store at controlled room temperature: 20°C to 25°C (68°F to 77°F).
• Protect from moisture, heat, and direct sunlight.
• Shake well before use if suspension.
• Do not freeze.
• Keep container tightly closed when not in use.^{[1] [4]}